期刊文献+

金黄色葡萄球菌氟喹诺酮的耐药性与grlA、grlB突变的关系 被引量:3

Relation between fluoroquinolones-resistant and mutation of grlA and grlB gene in Staphylococcus aureus
下载PDF
导出
摘要 为了探讨金黄色葡萄球菌的氟喹诺酮耐药性与grlA、grlB基因突变的关系,从52株野生型金黄色葡萄球菌中筛选出1株对氟喹诺酮敏感的金黄色葡萄球菌,对其进行耐药诱导,获得一系列不同氟喹诺酮耐药水平的金黄色葡萄球菌,并对其grlA、grlB基因进行PCR扩增、测序及序列分析。结果表明,金黄色葡萄球菌的氟喹诺酮耐药性与grlB基因突变无关,而与grlA的丝氨酸(Ser)80→苯丙氨酸(Phe)和谷氨酸(Glu)84→赖氨酸(Lys)突变密切相关。金黄色葡萄球菌grlA的80位氨基酸和84位氨基酸双突变是其氟喹诺酮耐药性提高的标志之一。 The purpose was to study the relation between fluoroquinolones-resistant and mutation of grlA and grlB gene in staphylococcus, aureus,the sensitive strain was induced with Ciprofloxacin to get grad-resistance strain of S, aureus, the grlA and grlB gene were amplified and sequenced by polymerase chain reaction. Sequence analysis showed that grlB gene had no mutation,while Ser 80→Phe and Glu 84→ Lys of the grlA gene happened. These assays demonstrated that Ser 80→Phe and Glu 84→Lys of the grlA mutation were the main mark of staphylococcus aureus to {luoroquinolones-resistant rising.
出处 《西北农林科技大学学报(自然科学版)》 CSCD 北大核心 2007年第9期5-9,共5页 Journal of Northwest A&F University(Natural Science Edition)
基金 国家自然科学基金项目(30170698) 吉林农业大学博士启动基金资助项目
关键词 金黄色葡萄球菌 氟喹诺酮 耐药性 grlA grlB 基因突变 Staphylococcus a ureus fluoroquinolone drug-resistance grlA grlB gene mutation
  • 相关文献

参考文献11

  • 1Yamagishi A,Kojima T,Oyamada Y,et al.Alterations in the DNA topoisomerase Ⅳ grlA gene responsible for quinolone resistance in Staphylococcus aureus[J].Antimicrob Agents Chemother,1996,40(5):1157-1163.
  • 2Ferrerol,Cameron B,Crouzet J.Analysis of gyrA and grlA Amutations in step wise-selected ciprofloxacin-resistantumtants of staphylococu saures[J].Antimicrob Agents Chemother,1995,39(7):1554-1558.
  • 3Takahashi H,Kikuchi T,Shoji S,et al.Characterization of gyrA,gyrB,grlA and grlB mutations in fluoroquinolones-resistant clinical isolates of Staphylococcus aureus[J].Antimicob Chemother,1998,42(1):49-57.
  • 4Wang T,Tanaka M,Sato K.Dectction of grlA and gyrA muta tions in 344 Staphylococcus aureus strains[J].Antimicrob Agents Chemother,1998,42(2):236-240.
  • 5Fournier B,Hooper D.Mutations in topoisomerase Ⅳ and DNA gyrase of Staphylococcusa ureus:novel pleiotropic effects on quinolone and coumarin activity[J].Antimicrob Agents Chemother,1998,42(1):121-128.
  • 6National Committee for Clinical Laboratory Standards.M100-S9 performance standarde for antimicrobial susceptibility testing;Nixth informational supplement[S].Wayne Pa:NCCLS,1999.
  • 7雷军,王浴生,黎世能.国产氟喹诺酮药物体外耐药性研究[J].中国抗生素杂志,1993,18(3):224-228. 被引量:18
  • 8萨姆布鲁克J 弗里奇EF 曼尼阿蒂斯T 著 金冬雁 黎孟枫 侯云德 译.分子克隆实验指南[M].北京:科学出版社,1993.19-23,55-56,304-315.
  • 9Ito H,Yoshida H,Bogaki-Shonai M,et al.Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus[J].Antimicrob Agents Chemother,1994,38(9):2014-2023.
  • 10Tanaka M,Onodera Y,Ariyoshik,et al.Inhibitory activities of quinolones against DNA gyrase and topoisomerase Ⅳ purified from staphylococcus[J].Amtimicrob Agents Chemother,1997,41(7):2362-2366.

二级参考文献1

  • 1J. T. Smith. Mutational resistance to 4-quinolone antibacterial agents[J] 1984,European Journal of Clinical Microbiology(4):347~350

共引文献31

同被引文献26

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部